Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. The analogy would be this. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

DECEMBER 9, 2021

The Financing is expected to close on December 10, 2021. The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

AUGUST 10, 2021

As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021. With these injustices, and many more, it is clear why many BIPOC might be disinterested in participating in such studies today.

Clinical Trials 105

Clinical Trials Research and Development Therapy Treatment 105

Cannabis Law Report

JUNE 21, 2021

June 14, 2021 – June 18, 2021. OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. PsyIndex Weekly Update. ATAI Life Sciences N.V. Market Performance. (OTC:

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Puff Puff Post

DECEMBER 28, 2018

The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Instead, CBD is being used.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — SciSparc Ltd. OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

AUGUST 13, 2021

Derived from Salvia divinorum, SalA is a unique non-nitrogenous agonist of the kappa-opioid receptor (KOR) with potential use in treatment-resistant depression (TRD), substance use disorder (SUD) and pain. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

AUGUST 22, 2021

16, 2021 /CNW/ — PsyBio Therapeutics Corp. The addition of methylated tryptamines with pending patent protection is focused on the potential improvement of treatments for mental health conditions including depression, anxiety and addiction, as well as other psychological and neurologic conditions. .”

Clinical Trials 98

Clinical Trials Research and Development Treatment Conditions 98

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. MedXtractor Corp.’s Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. Looking Ahead.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

The Cannigma

MARCH 7, 2022

A recent 2021 review of the literature found that there is simply no substantial evidence to back CBN’s claim to sedation and that more human research is needed. What can the current clinical trials tell us? Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.

THC 140

THC Clinical Trials Sleep Cannabinoids 140

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. 3 Nature Aging | VOL 1 | July 2021 | p. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. RADNOR, Pa.–(BUSINESS Data Highlights.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

JUNE 23, 2021

NEO: AWKN) began trading today, June 23, 2021, on the NEO Exchange Inc. The company has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021 (Bristol, London, and Manchester). David Nutt), starts in Q4 2021.

Clinical Trials 85

Clinical Trials Therapy Research and Development Treatment 85

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 23, 2021

Findings in The Pharmaceutical Cannabis Report: 2nd Edition include: The author estimates the market size for the three most widely used cannabinoid pharmaceuticals (Epidiolex, Sativex, Dronabinol) to be worth just under €900 million as of 2021, growing to €1.8 billion by 2025. The current medical cannabis market is bursting with innovation.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Veriheal

JANUARY 28, 2022

Rather, it was only an indication that CBD’s ability to fight COVID-19 warranted further research under more rigorous clinical trials. Nevertheless, CBD and other cannabis compounds may still prove to be effective COVID treatments. Nancy Mace of South Carolina in November 2021. In addition to these two active U.S.

Dispensary 98

Dispensary CBD Clinical Trials Legalization 98

Cannabis Law Report

JANUARY 14, 2022

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Right-to-try permits those patients to have access to investigational drugs.

Treatment 52

Treatment Access Clinical Trials Patients 52

Veriheal

MARCH 20, 2023

Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Connecticut Gov. Minnesota Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. The May 4, 2021 guidance for revenue was in the range of $2.5 – $2.7 That has been increased as of June 17, 2021, to a range of $3.0

Pharmaceutical 83

Pharmaceutical Clinical Trials Therapy Programs 83

LifeCannMD

MAY 27, 2025

What really opened my eyes was this study that came out in 2021. times more likely to achieve their treatment goals with medical cannabis. A 2021 study in Frontiers in Pharmacology showed that CBD enhances THC’s therapeutic effects while reducing anxiety and cognitive impairment.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. March 8, 2021). See June 8, 2021 Order, AIMS Institute et al. Id ; 21 CFR 312.1-10;

Law 81

Law Therapy Clinical Trials Decriminalization 81

Puff Puff Post

OCTOBER 3, 2019

Not only did the success influence the European Commission to approve Epidoliolex , but it also sparked motivation to develop a similar treatment for other disorders. It’s roughly estimated that the study results will be finalized by September of 2021, but a lot more research is still needed before any potential verdicts arise.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

SEPTEMBER 6, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. during 2021-2026. Cannabis is safer and has less severe side effects in comparison to other treatment options.

Chronic Pain 66

Chronic Pain Research and Development Clinical Trials Epilepsy 66

Cannabis Law Report

JUNE 11, 2021

NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Here’s the press release. This all could not have been possible without you.”.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960). USOTC: USMJ).

Treatment 52

Treatment Research and Development CBD Clinical Trials 52

Cannabis Law Report

JULY 29, 2021

VANCOUVER, BC , July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products.

Clinical Trials 105

Clinical Trials Conditions Packaging Events 105

Cannabis Law Report

JUNE 4, 2021

– Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Presenter: Dr. Scott Tagawa MD, MS, FACP.

Data 100

Data Research and Development Clinical Trials Therapy 100

TheAnswerPage

JUNE 19, 2021

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials 40

Clinical Trials Epilepsy Treatment CBD 40